1. Introduction {#sec1}
===============

Pulmonary Arterial Hypertension (PAH) is a progressive and devastating disease characterized by an increase in pulmonary vascular resistances (PVRi), causing right ventricular (RV) failure and death if not adequately treated.

Idiopathic Pulmonary Arterial Hypertension (IPAH) predominantly affects women of reproductive age. The disease could be diagnosed occasionally during pregnancy, with a high maternal and fetal mortality risk reported.

The management of IPAH during or after pregnancy is complex. Recent international Pulmonary Hypertension (PH) guidelines recommend initial combination therapy, including i.v. prostanoids, for high risk patients (pts) but few data are available on upfront triple combination therapy after delivery. Long-term response after discharge is largely unknown in these pts.

When epoprostenol is begun for a complete therapeutic approach, its withdrawal during follow-up is almost impossible, due to its potent and lifesaving role.

We present a case of complete 1-year RV reverse remodelling that allowed a down-titration until complete suspension of epoprostenol from the treatment regimen.

2. Case report {#sec2}
==============

A 36-year-old woman in the 34th gestational week of her first pregnancy presented to the emergency department with progressive severe dyspnea on exertion. She had no major illnesses and her mother died when she was 2 years old for a non-specified cardiopathy. Regular cardiac follow-up during pregnancy was normal until the 7th month.

She presented in sinus tachycardia (heart rate 135 beats per minute), with systemic hypotension (arterial blood pressure 75/40 mm Hg) and tachypnea (respiratory rate 35/min). On chest auscultation there were minimal bi-basilar rales and a grade IV holosystolic murmur.

Routine biochemistry, including auto-immunity screening, was normal except for NT-proBNP (11.000 pg/ml). ECG showed signs of RV overload. Arterial blood gases analysis revealed severe hypoxemia and hypocapnia (pO2 55 mm Hg, pCO2 22 mm Hg). Trans-thoracic echocardiography revealed severe RV dilatation (61 mm) with left ventricular (LV) compression (RV/LV 4), severe RV hypokinesia (TAPSE 13 mm) and elevated systolic pulmonary artery pressure (sPAP 100 mm Hg). After urgent Caesarean delivery, a CT pulmonary angiography was performed to exclude acute pulmonary embolism and acute pulmonary diseases, and completely negative. The baby was healthy. For severe hypotension and severe pre-capillary PH \[PAP s/d/m 110/48/69 mm Hg, Pulmonary Artery Wedge Pressure (PAWP) 13 mm Hg, Cardiac Index (CI) 1.7 L/min/m2, PVRi 33 WU\], she was treated with diuretics (furosemide 80 mg/24h) and inotropes (dobutamine 12 mcg/Kg/min and dopamine 6 mcg/Kg/min) to support circulation. Vasoreactivity test with inhaled nitric oxide (40 ppm for 10 minutes) was negative. Due to persistently poor clinical conditions, sildenafil 20 mg TID was initiated and rapidly up-titrated to 80 mg TID. On day-1, epoprostenol was not available in Emergency Unit. Despite sildenafil treatment, poor hemodynamic response was evident (PAP s/d/m 105/45/65 mm Hg, PAWP 10 mm Hg, CI 1.8 L/min/m2, PVRi 31 WU). On day-2 and after a multidisciplinary meeting, continuous i.v. infusion of epoprostenol (rapidly up-titrated to 15 ng/kg/min within 72 h from initiation) was started. Oral bosentan (62.5 mg BID) was added to back ground therapy on day-7. Significant hemodynamic response (PAP s/d/m 80/35/50 mm Hg, PAWP 9 mmHg, CI 3.3 L/min/m2, PVRi 12 WU) was recorded after 10 days of treatment regimen. The lady was discharged after 1 month of hospitalization with sildenafil 20 mg TID, bosentan 125 mg BID and epoprostenol 15 ng/kg/min (through a Groshong catheter). The dosage of sildenafil was down-titrated due to National Prescriprion Policy. Low doses of diuretics were maintained (50 mg/24h). Pre-discharge echocardiographic parameters were: RV diameter 42 mm, TAPSE 19 mm, RV/LV 1.4, sPAP 68 mm Hg.

Due to the progressive normalization of non-invasive parameters (NT-proBNP, 6 minute walk distance, echocardiographic parameters) after 3 months of triple combination therapies, epoprostenol was progressively reduced by 1 ng/kg/min every 4 weeks and finally stopped after 1 year of treatment. Hemodynamic assessment after epoprostenol withdrawal showed PAP s/d/m 31/11/20 mm Hg, PAWP 10 mm Hg, CI 3.06 L/min/m2, PVRi 3.26 WU. Echocardiographic parameters were: RV diameter 30 mm, TAPSE 22 mm, RV/LV 0.9, sPAP 33 mm Hg.

At present, after 2 years from epoprostenol withdrawal, she is still on combination therapy with sildenafil 20 mg TID and bosentan 125 mg BID. All non-invasive parameters are stable and she is in WHO class I with a quite normal functional activity. Her son is growing up healthy.

3. Discussion {#sec3}
=============

During pregnancy, blood volume increases up to 50% of the normal value. In normal subjects, adequate cardiac output is maintained through increase in heart rate and reduction of PVRi. This physiologic adaptation lacks in patients with PAH, for whom pregnancy is associated with a further increase in PAP and progressive RV dysfunction and dilatation. For this reason, pregnancy is contra-indicated in women suffering from PAH. With the introduction of specific PAH drugs, peri-partum mortality has decreased from 38% to 25%, but still remaining significantly high both for mothers and for babies [@bib1].

One of the major prognostic determinants in patients with PH is RV dysfunction. Long-term pressure overload in IPAH patients induces progressive RV remodelling, including myocardial hypertrophy, ventricular dilatation, tricuspid regurgitation and early diastolic ventricular septal bowing [@bib2]. In literature, there are some data on RV reverse remodelling in chronic thromboembolic pulmonary hypertension treated with thromboendoarterectomy or balloon pulmonary angioplasty [@bib3] and in IPAH after lung transplantation [@bib4]. The upfront use of a combined triple therapy with phosphodiesterase-5 inhibitors, endothelin-1 receptor antagonists and prostainoids has been recently described in patients with severe PAH in WHO class III-IV [@bib5]. This approach has been associated in some cases with normalization of RV function and PVRi. For this reason, the authors suggested its use, especially in extremely critical conditions.

We performed the same approach of Sitbon et al. in a pregnant woman that presented with a severe RV shock at time of delivery. Despite the initiation of epoprostenol as second treatment regimen (after only 1 day of delay), the rapid institution of the upfront triple combination therapy with bosentan, sildenafil and epoprostenol allowed a complete RV reverse remodelling after 1 year of epoprostenol therapy, leading to a quite normalization of clinical status (WHO class I), echocardiogaphic \[[Fig. 1](#fig1){ref-type="fig"}\], biohumoral and hemodynamic parameters. With a normalized RV function, epoprostenol could be down-titrated and sometimes withdrew, improving patient compliance to IPAH specific therapies.

In conclusion, we suggest that in very compromised pregnant at time of diagnosis, an upfront triple combination therapy could lead to a complete early RV reverse remodelling, improving significantly the survival time.
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